The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Digital tech in healthcare: Is this a time for change?
Covid-19 is accelerating the adoption of digital technology across the health sector. Dr Tom Oakley, CEO of Feedback Medical, stresses how the NHS should not miss the opportunity to rapidly adopt innovative remote working tools, particularly for diagnostics.
https://www.hospitaltimes.co.uk/digital-tech-in-healthcare-is-this-a-time-for-change/
Lambo, Bleepa Video Playlist has now launched. This should help with upgrading your knowledge of FDBK.
https://www.youtube.com/playlist?list=PL644i06zx6LtVTqrTS-a9uZiAs1piJ_4N
All small companies have associated risks. Don't listen to other people's opinions. Always do your own research. Start with what you can find on websites and move on from there.
Try these for starters. Good Luck.
https://fbkmed.com/
https://fbkmed.com/bleepa
https://futurehealthcare.software/project/bleepa-medical-communication/
https://imagingengineeringllc.com/about/
https://imagingendpoints.com/
https://www.businesscloud.co.uk/opinion/isolating-doctors-need-remote-tools-to-diagnose-patients
https://www.youtube.com/watch?v=Sj__mm0hcQ8
https://www.investegate.co.uk/Index.aspx?searchtype=3&words=fdbk
If, with huge emphasis on if, this order depth is true then there might be a large jump in price heading this way at some point.
Bid 200k at 1.3p - Ask 300k at 1.4p
Bid 200k at 1.2p - Ask 200k at 1.8p
https://fbkmed.com/feedback-plc/share-price/
Not an impossibility but certainly a self destructive act when you have options at 1.2p waiting to be claimed. A clever board of directors would ensure they have other options such as a government Covid-19 loan, a sale of TexRAD or money arriving from a left field source such as fluoroscopy equipment upgrades for example.
And mess up the options the board announced last week? I doubt it. Far more likely that TexRAD will be sold to a larger company and the funds from that used to increase the release of Bleepa both at home and abroad.
Matt is already aware of Bleepa.
Coronavirus research: who got the priority label from the government
https://www.proactiveinvestors.co.uk/companies/news/917962/coronavirus-research-who-got-the-priority-label-from-the-government-917962.html
"Feedback PLC’s (LON:FDBK) management tool Bleepa was also identified as being a secure solution to register and identify patients suitable for the RECOVERY trial."
That post provides a link to the Medic Bleep web site. I couldn't find any reference to 4,000 users on their own web site which is why I was concerned. I suppose it could be there somewhere but I can't see it.
https://www.medicbleep.com/features.html
Cannot find the suggested link from Elise1 and the Digital Health link that Gaz posted refers to 4,000 Grampian staff using Ascom UK’s i62 voice over WiFi (VoWiFi) handsets. There is no connection between Ascom i62's and Medic Bleep other than it being briefly mentioned independently later in the article.
Courtesy of Ged5 from over at the other place.
UK Imaging Platform for COVID-19 Management
https://healthmanagement.org/c/imaging/news/uk-imaging-platform-for-covid-19-management
A UK hospital Trust has launched a platform for secure communications based on medical image to support staff workflow of COVID-19 cases.
Named Bleepa, Pennine Acute Hospitals NHS Trust said it is rolling out the system immediately, for better management of its response to the virus and of infected patients.
The Trust has enrolled 200 acute medical front line clinicians Around 200 front line on Bleepa.
Medical imaging plays a big role in COVID-19 management through chest X-rays, CT scans and even ultrasound. Bleepa makes relevant imaging available and captures dialogue from clinicians. All of this data is added to the patient record after admission.
Bleepa enables clinicians to share, annotate and discuss medical-grade images and patient cases through their personal devices, working collaboratively while working remotely.
The app is also being deployed by the Trust to Bleepa for a trial run by research nurses assessing the recovery pathway of diverse COVID-19 patient groups
The Trust trialled Bleepa for several months leading to development of a more refined version of the app with a smart form for clinical data entry and the ability to designate patients with a clinical status.
This enhances ease of tracking as cases move through clinical pathways.
Why? Because a significant portion of the original Bleepa analysis, design and coding was undertaken by a Polish company and the primary testing of the product was undertaken by a group of people within the Polish health service. Only when it passed that testing phase did Feedback release a version for testing by the NHS team in the Pennines. Ergo, it should be a reasonable secondary market in which to make inroads.
The CE approval was granted two and a half years ago not five years as you suggest. Read all about it below.
https://www.investegate.co.uk/feedback-plc--fdbk-/rns/first-ce-marked-release-of-texrad--technology/201711200700059059W/
There was no rise in the share price back then. That was because a pernicious puddle of exudate started selling down his substantial holding almost immediately the CE Mark news was released. (See Adrianz's post earlier today at 12:07 for more detail.)
I don't believe that you can get any relevant information from that instance. The puddle has evaporated and the BoD has been replaced.
Skid, check these out.
1. Who owns this?
http://potstill.org/about/staff/
2. Who is a director and European Brand Ambassador here?
https://manlyspirits.com.au/our-team/